Zoetis Inc. logo
Zoetis Inc. (ZTS)
Compare

ZTS Cash Flow Statement

Operating, investing, and financing cash flow analysis

ZTS Quarterly Cash Flow Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Cash from Operations (CFO)
2.718B401.000M893.000M938.000M486.000M587.000M905.000M951.000M502.000M
2.643B601.000M603.000M721.000M718.000M631.000M581.000M682.000M624.000M
Depreciation & Amortization
487.000M119.000M121.000M124.000M123.000M119.000M123.000M121.000M127.000M
91.000M25.000M22.000M22.000M22.000M17.000M19.000M18.000M19.000M
Change in Accounts Receivable
6.177B1.506B1.590B1.541B1.540B1.361B1.316B1.411B1.383B
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-576.000M-385.000M170.000M54.000M-415.000M-217.000M309.000M360.000M-239.000M
Cash from Investing
-582.000M-110.000M-161.000M-133.000M-178.000M-149.000M-216.000M-167.000M-132.000M
-24.000M0.00-14.000M-10.000M0.000.00293.000M-1.000M-8.000M
Cash from Financing
Debt Repayment
-3.398B-606.000M-2.060B-394.000M-338.000M-443.000M-553.000M-433.000M-533.000M
-889.000M-224.000M-220.000M-222.000M-223.000M-224.000M-194.000M-197.000M-197.000M
2.136B291.000M732.000M805.000M308.000M438.000M689.000M784.000M370.000M
Net Change in Cash
82.000M-509.000M228.000M649.000M-286.000M-266.000M273.000M140.000M-401.000M

ZTS Annual Cash Flow Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Cash from Operations (CFO)
2.904B2.953B2.353B1.912B2.213B2.126B1.795B1.790B
2.673B2.486B2.344B2.114B2.037B1.638B1.500B1.428B
Depreciation & Amortization
487.000M497.000M491.000M465.000M448.000M441.000M412.000M308.000M
83.000M74.000M60.000M62.000M58.000M59.000M67.000M53.000M
Change in Accounts Receivable
1.590B1.316B1.304B1.215B1.133B1.013B1.086B1.036B
Change in Inventory
Change in Accounts Payable
Change in Working Capital
-408.000M79.000M-512.000M-699.000M-343.000M-85.000M-151.000M112.000M
Cash from Investing
-621.000M-655.000M-732.000M-586.000M-477.000M-453.000M-460.000M-338.000M
-24.000M285.000M-59.000M-312.000M-14.000M-113.000M-195.000M-1.998B
Cash from Financing
Debt Repayment
-3.235B-1.858B-1.092B-1.594B-743.000M-250.000M-626.000M-698.000M
-889.000M-786.000M-692.000M-611.000M-474.000M-380.000M-314.000M-243.000M
2.283B2.298B1.621B1.326B1.736B1.673B1.335B1.452B
Net Change in Cash
325.000M-54.000M-1.540B96.000M-119.000M1.670B332.000M38.000M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ
13,800 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Kristin C. Peck